Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · IEX Real-Time Price · USD
2.730
-0.030 (-1.09%)
At close: Jul 19, 2024, 4:00 PM
2.650
-0.080 (-2.93%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $376.85K in the twelve months ending May 31, 2024, with 22.90% growth year-over-year. Revenue in the quarter ending May 31, 2024 was $84.00K with 8.10% year-over-year growth. In the fiscal year ending August 31, 2023, Lexaria Bioscience had annual revenue of $226.21K.
Revenue (ttm)
$376.85K
Revenue Growth
+22.90%
P/S Ratio
114.53
Revenue / Employee
$75,369
Employees
5
Market Cap
43.16M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
Aug 31, 2019 | 222.61K | -210.68K | -48.62% |
Aug 31, 2018 | 433.29K | 369.65K | 580.85% |
Aug 31, 2017 | 63.64K | 22.92K | 56.29% |
Aug 31, 2016 | 40.72K | 26.02K | 176.96% |
Aug 31, 2015 | 14.70K | - | - |
Aug 31, 2014 | 0 | - | - |
Oct 31, 2013 | 0 | - | - |
Oct 31, 2012 | 1.36M | 224.00K | 19.76% |
Oct 31, 2011 | 1.13M | 771.30K | 212.79% |
Oct 31, 2010 | 362.47K | -59.48K | -14.10% |
Oct 31, 2009 | 421.96K | -478.83K | -53.16% |
Oct 31, 2008 | 900.79K | 647.64K | 255.83% |
Oct 31, 2007 | 253.15K | 232.84K | 1,146.60% |
Oct 31, 2006 | 20.31K | - | - |
Oct 31, 2005 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NeueHealth | 1.11B |
Fortress Biotech | 85.11M |
Qilian International Holding Group | 46.47M |
BioXcel Therapeutics | 1.76M |
OncoCyte | 1.38M |
Envoy Medical | 297.00K |
LEXX News
- 4 days ago - Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study - Accesswire
- 5 days ago - Lexaria Preparing For Strategic Growth - Accesswire
- 12 days ago - Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study - Accesswire
- 13 days ago - Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy - Accesswire
- 4 weeks ago - Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study - Accesswire
- 6 weeks ago - Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study - Accesswire
- 2 months ago - Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study - Accesswire
- 2 months ago - Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study - Accesswire